927 related articles for article (PubMed ID: 21529740)
21. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.
Ozhan H; Erden I; Ordu S; Aydin M; Caglar O; Basar C; Yalcin S; Alemdar R
Angiology; 2010 Oct; 61(7):711-4. PubMed ID: 20395226
[TBL] [Abstract][Full Text] [Related]
22. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
Fu N; Liang M; Yang S
Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
[TBL] [Abstract][Full Text] [Related]
23. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.
Khanal S; Attallah N; Smith DE; Kline-Rogers E; Share D; O'Donnell MJ; Moscucci M
Am J Med; 2005 Aug; 118(8):843-9. PubMed ID: 16084176
[TBL] [Abstract][Full Text] [Related]
24. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
[TBL] [Abstract][Full Text] [Related]
25. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
26. [Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
Su JZ; Xue Y; Cai WQ; Huang QY; Chai DJ; Chen GL; Wang FB; Chen XP; Zhang DS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Sep; 39(9):807-11. PubMed ID: 22321227
[TBL] [Abstract][Full Text] [Related]
27. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
Patti G; Chello M; Gatto L; Alfano G; Miglionico M; Covino E; Di Sciascio G
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):795-800. PubMed ID: 20613550
[TBL] [Abstract][Full Text] [Related]
28. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
29. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A Meta-analysis of Randomized Controlled Trials.
Liu YH; Liu Y; Duan CY; Tan N; Chen JY; Zhou YL; Li LW; He PC
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):181-92. PubMed ID: 25193735
[TBL] [Abstract][Full Text] [Related]
30. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
Worasuwannarak S; Pornratanarangsi S
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
[TBL] [Abstract][Full Text] [Related]
31. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
32. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Hahn JY; Kim HJ; Choi YJ; Jo SH; Kim HJ; Lee S; Ahn KJ; Song YB; Choi JH; Choi SH; Choi YJ; Lee KH; Lee SH; Gwon HC
Am Heart J; 2011 Dec; 162(6):1026-33. PubMed ID: 22137076
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
[TBL] [Abstract][Full Text] [Related]
34. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis.
Zhang BC; Li WM; Xu YW
Can J Cardiol; 2011; 27(6):851-8. PubMed ID: 21944277
[TBL] [Abstract][Full Text] [Related]
35. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
Liang M; Yang S; Fu N
Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
[TBL] [Abstract][Full Text] [Related]
37. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
[TBL] [Abstract][Full Text] [Related]
38. Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention.
Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovičová L; Tomašov P; Tesař D
Am J Cardiol; 2011 May; 107(9):1295-9. PubMed ID: 21349484
[TBL] [Abstract][Full Text] [Related]
39. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
